drugset / Trial / NCT06474663
A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To find the recommended dose of the drug combination cladribine, cytarabine, decitabine, and sorafenib in participants with relapsed/refractory AML, MPAL, and ALAL.
Timeline
- Start
- 2025-07-31
- Primary completion
- 2025-07-31
- Completion
- 2025-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cladribine | Small molecule | — | Intravenous |
| Subject | Cytarabine | Small molecule | — | Subcutaneous |
| Subject | Decitabine | Small molecule | — | Intravenous |
| Subject | Sorafenib | Small molecule | — | Oral |